Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor

被引:10
作者
Burch, Jason D. [1 ]
Farand, Julie [1 ]
Colucci, John [1 ]
Sturino, Claudio [1 ]
Ducharme, Yves [1 ]
Friesen, Richard W. [1 ]
Levesque, Jean-Francois [2 ]
Gagne, Sebastien [2 ]
Wrona, Mark [2 ]
Therien, Alex G. [3 ]
Mathieu, Marie-Claude [3 ]
Denis, Danielle [3 ]
Vigneault, Erika [3 ]
Xu, Daigen [4 ]
Clark, Patsy [4 ]
Rowland, Steve [4 ]
Han, Yongxin [1 ]
机构
[1] Merck Frosst Canada Ltd, Dept Med Chem, Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
[2] Merck Frosst Canada Ltd, Dept DMPK, Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
[3] Merck Frosst Canada Ltd, Dept In Vitro Sci, Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
[4] Merck Frosst Canada Ltd, Dept In Vivo Sci, Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
关键词
Naphthalene/quinoline amides and sulfonylureas; EP4 receptor antagonist; Inflammatory pain; PROSTANOID RECEPTORS; COX-2; INHIBITORS; CANCER CELLS; PROMOTES; EXPRESSION; GROWTH; PAIN; INFLAMMATION; METASTASIS; REDUCTION;
D O I
10.1016/j.bmcl.2010.12.014
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two new series of EP4 antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1041 / 1046
页数:6
相关论文
共 37 条
[1]   The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs [J].
Abramovitz, M ;
Adam, M ;
Boie, Y ;
Carrière, MC ;
Denis, D ;
Godbout, C ;
Lamontagne, S ;
Rochette, C ;
Sawyer, N ;
Tremblay, NM ;
Belley, M ;
Gallant, M ;
Dufresne, C ;
Gareau, Y ;
Ruel, R ;
Juteau, H ;
Labelle, M ;
Ouimet, N ;
Metters, KM .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1483 (02) :285-293
[2]   A direct synthesis of 1-aryl- and 1-alkenylcyclopropylamines from aryl and alkenyl nitriles [J].
Bertus, P ;
Szymoniak, J .
JOURNAL OF ORGANIC CHEMISTRY, 2003, 68 (18) :7133-7136
[3]   The Discovery of 4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic Acid (MK-2894), A Potent and Selective Prostaglandin E2 Subtype 4 Receptor Antagonist [J].
Blouin, Marc ;
Han, Yongxin ;
Burch, Jason ;
Farand, Julie ;
Mellon, Christophe ;
Gaudreault, Mireille ;
Wrona, Mark ;
Levesque, Jean-Francois ;
Denis, Danielle ;
Mathieu, Marie-Claude ;
Stocco, Rino ;
Vigneault, Erika ;
Therien, Alex ;
Clark, Patsy ;
Rowland, Steve ;
Xu, Daigen ;
O'Neill, Gary ;
Ducharme, Yves ;
Friesen, Rick .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :2227-2238
[4]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[5]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[6]   Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor [J].
Burch, Jason D. ;
Belley, Michel ;
Fortin, Rejean ;
Deschenes, Denis ;
Girard, Mario ;
Colucci, John ;
Farand, Julie ;
Therien, Alex G. ;
Mathieu, Marie-Claude ;
Denis, Danielle ;
Vigneault, Erika ;
Levesque, Jean-Francois ;
Gagne, Sebastien ;
Wrona, Mark ;
Xu, Diagen ;
Clark, Patsy ;
Rowland, Steve ;
Han, Yongxin .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) :2048-2054
[7]   Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence [J].
Chell, SD ;
Witherden, AR ;
Dobson, RR ;
Moorghen, M ;
Herman, AA ;
Qualtrough, D ;
Williams, AC ;
Paraskeva, C .
CANCER RESEARCH, 2006, 66 (06) :3106-3113
[8]   Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human [J].
Cipollone, F ;
Fazia, ML ;
Iezzi, A ;
Cuccurullo, C ;
De Cesare, D ;
Ucchino, S ;
Spigonardo, F ;
Marchetti, A ;
Buttitta, F ;
Paloscia, L ;
Mascellanti, M ;
Cuccurullo, F ;
Mezzetti, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) :1925-1931
[9]   MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis [J].
Clark, Patsy ;
Rowland, Steven E. ;
Denis, Danielle ;
Mathieu, Marie-Claude ;
Stocco, Rino ;
Poirier, Hugo ;
Burch, Jason ;
Han, Yongxin ;
Audoly, Laurent ;
Therien, Alex G. ;
Xu, Daigen .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (02) :425-434
[10]   Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoicacid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain [J].
Colucci, John ;
Boyd, Michael ;
Berthelette, Carl ;
Chiasson, Jean-Francois ;
Wang, Zhaoyin ;
Ducharme, Yves ;
Friesen, Rick ;
Wrona, Mark ;
Levesque, Jean-Francois ;
Denis, Danielle ;
Mathieu, Marie-Claude ;
Stocco, Rino ;
Therien, Alex G. ;
Clarke, Patsy ;
Rowland, Steve ;
Xu, Daigen ;
Han, Yongxin .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) :3760-3763